NEWS & EVENTS

Latest news and upcoming events

Memo Therapeutics increases Series C financing to CHF 45 million
07 May 2024

Memo Therapeutics increases Series C financing to CHF 45 million

Upcoming events

  • Bio€quity Europe
    14 - 16 May 2024,
    San Sebastián

    download

  • AseBio Investor Day 2024
    15 May 2024,
    San Sebastián

    download

  • ESMO Congress 2024
    13 - 19 September 2024,
    Barcelona

    download
CorWave to set up its manufacturing facility and expand to a new site next to Paris<
17 Mar 2022

CorWave to set up its manufacturing facility and expand to a new site next to Paris

The industrial start-up is preparing to move to larger premises capable of hosting its R&D center and the manufacturing facility needed to enter the clinical and commercial phases.
Aura Biosciences to Host Virtual Investor Day Focused on Ocular Oncology with Key Thought Leaders on March 22<
15 Mar 2022

Aura Biosciences to Host Virtual Investor Day Focused on Ocular Oncology with Key Thought Leaders on March 22

The program will include an overview of choroidal melanoma (CM), AU-011’s novel mechanism of action.
LAVA Therapeutics To Present at the Oppenheimer 32nd Annual Healthcare Conference 2022<
10 Mar 2022

LAVA Therapeutics To Present at the Oppenheimer 32nd Annual Healthcare Conference 2022

The recording will be available following the conference under the "Events" tab on the investor relations section of the LAVA Therapeutics
Kala Pharmaceuticals Announces EYSUVIS® Now Covered on UnitedHealthcare Commercial and Cigna Medicare<
08 Mar 2022

Kala Pharmaceuticals Announces EYSUVIS® Now Covered on UnitedHealthcare Commercial and Cigna Medicare

Expands Commercial Coverage to 118 million lives and Medicare Coverage to 7.1 million lives
Lava Therapeutics presents initial LAVA-051 clinical data at the ESMO Targeted Anticancer Therapies Congress 2022<
08 Mar 2022

Lava Therapeutics presents initial LAVA-051 clinical data at the ESMO Targeted Anticancer Therapies Congress 2022

LAVA-051 preliminary data shows encouraging initial clinical safety; no dose-limiting toxicity or cytokine release syndrome
Aura Biosciences to Present Preclinical Data Highlighting AU 011’s Potential to Target a Broad Number of Tumor Types at the 2022 AACR Annual Meeting<
08 Mar 2022

Aura Biosciences to Present Preclinical Data Highlighting AU 011’s Potential to Target a Broad Number of Tumor Types at the 2022 AACR Annual Meeting

The results demonstrate the potential wide applicability of AU-011 in targeting a number of solid tumor types
Am-Pharma announces two presentations at the 27th international conference on advances in critical care nephrology<
07 Mar 2022

Am-Pharma announces two presentations at the 27th international conference on advances in critical care nephrology

New data underscoring the correlation between acute kidney injury severity and patient outcomes following cardiac surgery.
Ysios Capital strengthens its team with the appointment of Thomas Harth as Principal<
04 Mar 2022

Ysios Capital strengthens its team with the appointment of Thomas Harth as Principal

This key addition will strengthen the Ysios Capital team, which is currently investing its fund Ysios BioFund III.
Galecto Reports Financial Results for the Year Ended December 31, 2021<
17 Feb 2022

Galecto Reports Financial Results for the Year Ended December 31, 2021

Continued pipeline progress with three potentially first-in-class product candidates
SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline<
16 Feb 2022

SpliceBio Raises EUR 50M in Oversubscribed Series A financing to Advance Protein Splicing Platform and Expand Gene Therapy Pipeline

Largest Series A round for a Spanish biotech company.

Newsletter

subscribe

Subscribe to our weekly newsletter for the latest
updates on life sciences investments.

Bitplex 360 Кракен даркнет кракен даркнет Blacksprut Blacksprut Кракен ссылка кракен ссылка